cyrilzakka/clinical-trials huggingface dataset:
Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases

The purpose of this study is to find out whether giving one higher dose of radiation is as good at treating the tumor in the patient's spine after surgery as giving three lower doses of radiation.


Eligibility Criteria:
Inclusion Criteria:

* Histologically diagnosed metastatic cancer (Diagnosis made or confirmed at MSKCC for MSKCC participants. Institutional pathologic determination accepted from participating multicenter sites.)
* Age ≥18 years
* Life expectancy ≥3 months
* ECOG ≤ 3
* Spinal surgery carried out with the goal of spinal cord decompression and spinal stabilization within 8 weeks
* Post-operative CT myelogram or MRI perfusion with evidence of separation of tumor and the spinal cord It should be noted that patients with multiple lesions will be eligible as long as there are no overlapping fields of radiation, including at various time frames.

Exclusion Criteria:

* Primary spine tumor
* Age \< 18
* Pregnancy
* Lack of adequate (≥ 2 mm) separation between the spinal cord and the tumor on post-operative CT myelogram or MRI perfusion
* Radiosensitizing chemotherapy (taxol, taxotere, cisplatin, gemcitabine, 5-fluorouracil) given within one week of radiation treatment
Comparison of Congenital Pneumonia and Transient Tachypnea of the Newborn

Accurate and timely differentiation between transient tachypnea of the newborn (TTN) and congenital pneumonia is essential in neonatal care, as it facilitates prompt initiation of appropriate treatment, reduces the risk of complications, and minimizes inappropriate antibiotic use. This study aims to assess the clinical utility of inflammatory markers, including the Systemic Immune-Inflammation Index (SII) and the Systemic Immune-Response Index (SIRI), in distinguishing TTN from congenital pneumonia in neonates. In scenarios where conventional diagnostic methods prove insufficient, these indices may offer clinicians a reliable and objective diagnostic approach, thereby optimizing antibiotic stewardship and reducing the duration of hospitalization.

Patients admitted to the Neonatal Intensive Care Unit of Dr. Behçet Uz Children's Hospital for respiratory distress will be analyzed.

The following data will be recorded in the "case report form" for each patient: age, gender,Score for Neonatal Acute Physiology- Perinatal Extension-II (SNAPPE-II), birth weight (SGA/LGA), mode of delivery (elective/emergency C-section and vaginal delivery), gravidity, parity, maternal age, maternal comorbidities (GDM, preeclampsia/eclampsia, hypothyroidism, chorioamnionitis, urinary tract infection, asthma, obesity, epilepsy), presence of premature rupture of membranes or fever, sibling history, low APGAR score (\<7), leukocyte count, neutrophil count, lymphocyte count, platelet count, monocyte count, aspartate transferase (AST), C-reactive protein (CRP), blood smear test, blood culture, tracheal aspirate culture, antibiotics used and their duration, chest X-ray findings, length of hospital stay, onset and duration of oxygen therapy and method of administration, need for mechanical ventilation, and morbidity and mortality status.

Eligibility Criteria:
Inclusion Criteria:

* Neonates born at ≥37 weeks of gestation, Admitted within the first 24 hours after birth with respiratory distress and a preliminary diagnosis of TTN

Exclusion Criteria:

* Congenital anomalies Genetic syndromes Diagnosis of sepsis Patients without informed consent
Post-operative Pulmonary Function After Kidney Surgery Under Two Different Techniques

To assess the respiratory and analgesic effects of continuous thoracic paravertebral block versus thoracic epidural in patients undergoing kidney surgery

Study tools

* An Ultrasound machine (Madison X6) with superficial linear and curved probe.
* A 19 gauge echogenic needle and Plexolong Cather (PAJUNK, Plexolong Meier nanoline, Geisingen, Germany; 60 mm).
* A 17-gauge Tuohy needle and 19 G flex-tip catheter: for thoracic epidural.
* Spirometer: (Enraf-Nonius, Model SPIRO 601).
* Drugs: isobaric bupivacaine 0.25% (aside from the drugs used in the standard operation theatre).
* Computer software: computer generated random tables (for randomization) and SPSS 22 (for data analysis)

Thoracic epidural (TEP):

A pre-procedural ultrasound examination will be done to first identify the correct targeted thoracic level. To accomplish this, the transducer will be placed in the parasagittal plane approximately 5 cm from midline. The thoracic level will be determined by identifying the 12th rib and counting in a cephalad direction until the targeted level is marked.

All epidurals will be performed under all aseptic precautions with a 17-gauge Tuohy needle and 19 G flex-tip catheters. Using the loss of resistance to saline technique, catheters will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection

Bupivacaine 0.25% of 7.5-12 ml volume will be given through the epidural catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h with bolus infusion of 5 to 10 ml of the infusion mixture for breakthrough pain. The block height will be tested using pin prick method. After spirometry testing and diaphragmatic ultrasound, the infusion of TEP will be gradually weaned of and the catheter will be removed under complete aseptic precautions.

Thoracic paravertebral block: (TPVB) The Ultrasound-probe will be centered on T7. The sagittal technique at the transverse process, in-plane, will be used. The 19 gauge echogenic needle will be inserted in-plane at the lower border of the transducer and advanced in a cephalad position with real-time ultrasound sonography.

Injection of small amounts of fluid (hydro-dissection) will aid in needle tip location. When the needle tip reaches the paravertebral space, 7.5-12 ml Bupivacaine 0.25% will be slowly injected after negative aspiration. The endpoint for a successful block is anterior displacement of the pleura. The catheter will be then inserted through the needle and positioned up to 3 cm from skin entry directing upwards in the paravertebral space then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h with bolus infusion of 5 to 10 ml of the infusion mixture for breakthrough pain.

Eligibility Criteria:
Inclusion Criteria:

* ASA II, III
* elective kidney surgery

Exclusion Criteria:

* patient refusal
* contraindications to neuraxial blocks
* pneumonectomy
* planed postoperative mechanical ventilatoin
Ex-vivo Evaluation of the Effect of 2 Probiotic Solutions (Lactibiane ATB and Lactibiane Enfant) and 5 Classes of Drugs on the Intestinal Microbiota

The objective is to test ex-vivo the effects of two probiotic solutions (Lactibiane ATB and Lactibiane Enfant) and five classes of drugs (antibiotic, proton pump inhibitor, non-steroidal anti-inflammatory, anxiolytic and anti-depressant) on microbial microcosms derived from human stool samples (from adults and children) re-cultured under anaerobic conditions.


Eligibility Criteria:
Inclusion Criteria:

Adult "Mother" population:

* Women aged 25-40 years;
* In good general health, i.e. no chronic pathology and not taking any medication at the time of inclusion and/or long-term treatment,
* With a regular bowel movement frequency (at least once every 2 days)
* BMI between 18.5 and 25
* Able and willing to participate in the research by complying with the protocol procedures
* Not objecting to the collection and processing of their personal data

Child "Daughter" population

* Girl between 1 and 2 years old
* In good general health, i.e. no chronic pathology and not taking any medication at the time of inclusion and/or on a long-term basis,
* With a regular stool frequency (at least once every 2 days)
* Whose mother does not object to the collection and processing of personal data

Exclusion Criteria:

Adult "Mother" population :

* Pregnant or breastfeeding women,
* Under antibiotic treatment, or having stopped it for less than a month.
* Under dietary supplementation (prebiotics or probiotics) or having stopped it less than one month before
* On antidepressants and/or anxiolytics in the month before inclusion
* Taking a non-steroidal anti-inflammatory drug (NSAID) the month before inclusion.
* On PPI, or having stopped it less than one month before.
* Persons under court protection,
* Person participating in another research study with an ongoing exclusion period,

Child "Daughter" population:

* Outside the WHO normal growth charts (weight for height) for girls aged 0-2 years (below the 3rd percentile or above the 97th percentile)
* Undergoing antibiotic treatment, or having stopped it less than a month ago.
* Having taken a non-steroidal anti-inflammatory drug (NSAID) in the month prior to inclusion.
* On dietary supplements (prebiotics or probiotics) or having stopped them within the last month
* Subjects participating in another research study with an ongoing exclusion period
Validation of the Two-minute Walk Test and the Ten-meter Walk Test in Individuals With Cancer

The aim of this study is to assess the feasibility and the validity of the 2-minute walk test (2MWT) and the 10-meter walk test (10MeWT) compared to the 6-minute walk test (6MWT) for subjects with onco-hematological disease.

Cancer and its treatments have an impact on the body as a whole. The analysis of the subject's physical capacity is essential to know the basic level of the subject pre-treatment, to evaluate progress following rehabilitation, to set goals to prevent decline in physical capacity or to evaluate changes in physical capacity at different stages of survival. The 6-minute walk test (6MWT) is frequently used in the clinic to assess the physical capacity of the subject in oncology. A variant of the 6MWT exists and has been little studied in an oncological context: the 2-minute walk test (2MWT). The 2MWT is performed in the same way as the 6MWT: the same instructions and the same test procedure. It offers the advantage of being less tiring for the test subjects and saves clinicians time. The 2MWT has been validated in the past for people with COPD or after cardiac surgery. To our knowledge, it has not been validated for cancer patients.

The 10-meter walk test (10MeWT) is frequently used in practice to assess patients' functional capacity. It would be another way to assess the walking ability with a short test.

However, the relationship between the 2MWT, 6MWT and 10MeWT in an oncological context remain unclear.

Eligibility Criteria:
Inclusion Criteria:

* Have an onco-hematologic disease
* Have medical authorization from the patient's oncologist authorizing gait tests
* Participate in the HUG rehabilitation program
* Be able to give consent by signature
* To be of legal age
* Do not present pain when walking more than 2/10
* Be able to walk with or without technical aids for a period of 6 minutes (as per patient's statement)

Exclusion Criteria:

* Suffer from heart problems
* Bone metastases at risk of fracture
* Osteoporosis at high risk of fracture
* Unbalanced Hypertension (hypertension)
* Not being able to carry out the walk tests in their entirety
* Not being able to perform the gait tests for reasons related to the side effects of the treatments (anemia, undernutrition, vomiting, severe fatigue, risk of thrombocytopenia, pain).
* Not being able to carry out the walking test because of a lack of understanding of the instructions or because of psychological problems.
Does Icodextrin Reduce the Risk of Small Bowel Obstruction?

The study aims at investigating if icodextrin 4% instilled in abdominal cavity during surgery can reduce the risk of surgery and hospitalisation for small bowel obstruction in patients with colorectal cancer. Follow-up data is collected from the Swedish national colorectal cancer registry.Patients are followed for 5 years postoperatively.The study is a randomized Swedish multicenter study and planned to include 1,800 patients. A safety control is planned after 300 included patients.

Icodextrin 7.5% is used in peritoneal dialysis. In animal models and in gynecological surgery a 4% solution of Icodextrin has been tested as a possible agent of reducing adhesions by acting as a barrier between peritoneal surfaces. Some data support a reduction af adhesions (van den Tool et al., Brown et al.). However, is not known whether icodextrin reduces the need for surgery or hospitalisation for small bowel obstruction.This study aims to study these parameters as well as complications and survival.

Patients with colorectal cancer and scheduled for surgery with curative intent will be (after patients acceptance) randomized to have icodextrin 4% instilled in the abdominal cavity or not. Patients allocated to icodextrin arm will have 100 ml of icodextrin 4% instilled every 30 minutes during surgery and at end of operation further 1000 ml instilled in the abdominal cavity. Postoperative care is performed according to each hospital praxis.

Follow-up data will be collected from the Swedish National Colorectal cancer registry. Data 30 days postoperatively will be analysed for early small bowel obstruction and other early complications. The study ends 5 years postoperatively with analysis of surgery and hospitalization for small bowel obstruction as well as survival and longterm complications.

A safety analysis is planned after the first 300 randomized patients with respect to early (30 days) complications. These data will analysed blindly by external reviewers.

Randomization (1:1) will be performed at the Regional Cancer Centrum in the Uppsala-Örebro region. The study aims to randomise 1800 patients.

Eligibility Criteria:
Inclusion Criteria:

* Colorectal cancer
* Curative surgery planned
* Informed consent
* Age 18-85

Exclusion Criteria:

* Local surgery planned
* Generalized disease
* Other malignancy
* Not informed consent
A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

The purpose of this study is to evaluate the distribution of IncobotulinumtoxinA (Xeomin) in healthy subjects at different volumes, concentrations and doses when administered intradermally and subcutaneously using different delivery methods (conventional needle and microneedles).


Eligibility Criteria:
Inclusion Criteria:

* Healthy male or female subject aged 18 to 45 years with body mass index (BMI) 19.0 to 27.0 kg/m².
* Subject with the distance not less than 45 cm between the spinous process of the 7th cervical vertebra (C7) and the 4th lumbar vertebra (L4).
* Healthy skin at test area (forehead and back).
* Fitzpatrick skin type I to IV.
* Displaying uniform sweating activity (i.e., symmetrical sweating pattern with enough sweat and without anhidrotic regions) on the forehead area as assessed with Minor's starch iodine test under standardized sweating conditions.

Exclusion Criteria:

* Any chronic pain conditions or presence of acute pain of any origin and intensity.
* Dermal treatment of the forehead (e.g., light resurfacing, dermabrasions) within the last 12 months before Screening, during the screening period, and/or at Baseline.
* Any type of filler in the treatment area on the facial region within the last 12 months before Screening, during the screening period, and/or atBaseline; regardless of time for any type of implant and/or surgery in the treatment area on facial region.
* Any type of surgery in the treatment area of the back within the last 12 months before Screening, during the screening period, and/or at Baseline.
* Treatment with anticholinergics within the last 14 days before Screening, during the screening period, and/or at Baseline.
* Treatment with analgesics (e.g., non steroidal anti inflammatory drugs, except acetylsalicylic acid, ibuprofen, and paracetamol) within the last 10 days before Screening, during the screening period, and/or prior to pain assessment at Baseline.
* Treatment with paracetamol, ibuprofen, or acetylsalicylic acid within three days prior to pain assessment at Baseline.
* Subjects with excessive sweating or previously diagnosed with hyperhidrosis.
Efficacy of CPR Teaching in Mass Training

This prospective study evaluate teaching efficacy of CPR training using different methods in general population, medical students and non medical students with the 12 months evaluation of its recall

In a prospective and observational study of 2000 individuals in three different groups including medical students, non-medical students and general populations four different protocols of CPR training were applied and their efficacy were compared between the groups. Meanwhile, 12 months after the study course, 460 participants from three groups were asked to take part in a theoretical and practical exam to evaluate the long term efficacy of the four protocols.

Eligibility Criteria:
Inclusion Criteria:

* all participant take part in workshop

Exclusion Criteria:

* refuse to take part in exams
Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent Patient

The principal objective is to evaluate the analgesic effectiveness of the systemic ketamine on the control of the pain (average consumption of morphine at 48 hours) at the alcool-dependent patient, in carcinological surgery ORL. The effect coanalgesic is found for low dose of ketamine and action anti NMDA seems to have a stabilizing effect on this particular type of patient. This imbalance of the receivers, with a greater number of r-NMDA among these patients would involve it a better analgesic effectiveness and less effects dysphoric, to see an improvement on the syndrome of weaning. The secondary objectives evaluate the pain, the ground (dependence with alcohol), the first request analgesic, the tolerance and the signs psychic (syndrome of weaning...) and the satisfaction of the patient.

The principal objective is to evaluate the analgesic effectiveness of the systemic ketamine on the control of the pain (average consumption of morphine at 48 hours) at the alcool-dependent patient, in carcinological surgery ORL. The effect coanalgesic is found for low dose of ketamine and action anti NMDA seems to have a stabilizing effect on this particular type of patient. This imbalance of the receivers, with a greater number of r-NMDA among these patients would involve it a better analgesic effectiveness and less effects dysphoric, to see an improvement on the syndrome of weaning. The secondary objectives evaluate the pain, the ground (dependence with alcohol), the first request analgesic, the tolerance and the signs psychic (syndrome of weaning...) and the satisfaction of the patient.

Eligibility Criteria:
Inclusion Criteria:

* patient alcohol-dependent having to undergo a carcinological surgery ORL with tracheotomy or tracheostomy, ASA 1-3

Exclusion Criteria:

* refusal of the patient
* counter-indications with the treatments,
* urgency
* the specific clinical context (final neoplasy, reanimation)
* the treatments for chronic pain containing morphinic
Substance Use Screening Among Drug User

The purpose of this research is to improve the ability of primary medical staffs in screening and intervention for alcohol, benzodiazepines, and other illicit drug use.

In order to reduce the social and personal harm caused by drugs, it is urgent to strengthen the ability of the primary health institutions in screening and intervention the addictive substances use. Firstly, the investigators will invite 10 primary medical staffs and 10 experts in addition to revise the manual of Alcohol, Smoking, and Substance Use Involvement Screening Test (ASSIST) and Brief Intervention (BI). Then, the investigators will recruit 100 medical staffs to participate the training of ASSIST and BI. Secondly, the researcher will investigate the effects of BI technology in reducing the use of addictive substances, improve the addiction related knowledge of patients through randomized controlled study. Finally, the investigators will collect the research information, revise the manual, and promote the training.

Eligibility Criteria:
Inclusion Criteria:

1. aged 18-60 years;
2. the patient to the community medical institutions;
3. ASSIST score is in 12-27, in a moderate risk;
4. voluntary to participate;
5. to agree to complete baseline interviews and follow-up studies.

Exclusion Criteria:

1. unable to complete the questionnaire;
2. serious physical illness, action inconvenience.
Interaction Between Fluvoxamine and Sildenafil

Aim of the study is to assess the interaction between sildenafil and fluvoxamine and its effect on the venous response to sodium nitroprusside.

In a randomised, double-blind, placebo-controlled, cross-over study in healthy men we will assess the effect of oral fluvoxamine (50mg qd on day 1-3; 100mg qd on day 4-10) on sildenafil kinetics (single oral 50mg dose on day 11). Sildenafil plasma concentrations will be determined by LC/MS. We will also assess the effect of sildenafil on venodilation induced by a constant dose-rate of the NO-donor sodium nitroprusside (SNP) during preconstriction with phenylephrine (dorsal hand vein compliance technique).

Eligibility Criteria:
Inclusion Criteria:

* Healthy, male individuals, age: 18-45.
* Able and willing to give written informed consent

Exclusion Criteria:

* Hypotension ( 65 mmHg diastolic and  100 mmHg systolic blood pressure)
* Bleeding disorders in medical history
* Intake of medication impairing platelet function or influencing coagulation (for example aspirin, NSAID and others) during the preceding 4 weeks
* Known condition causing endothelial dysfunction (e.g. diabetes, hyperlipidaemia, arterial hypertension, hyperhomocysteinaemia, smoking)
* Anatomic deformity of the penis like angulation, penile fibromatosis (peyronie's disease) or diseases favouring priapism (e.g. leukaemia, plasmocytoma, sickle-cell anaemia)
* Regular medication and/or treatment with drugs within the preceding 4-6 weeks (exclusion has to be decided in each case)
* alcohol (\>30 g/d) or drug abuse
* Acute or chronic illness
* Blood donation within the preceding 2 months
* Participation in clinical trial within 2 month before the study
* Drug and/or alcohol abuse.
Topic Cervical Anesthesia Plus Paracervical Blockade for Pain Control During Endouterine Manual Aspiration

To compare the effectiveness of lidocaine gel plus paracervical blockade vs. lidocaine gel alone in the management of pain during endouterine manual aspiration.


Eligibility Criteria:
Inclusion Criteria:

* Need for a endouterine manual aspiration (incomplete abortion or gynecological bleeding).

Exclusion Criteria:

* Allergy to lidocain